150 related articles for article (PubMed ID: 30120701)
1. Genetic polymorphisms of 3'-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy.
Sanchez-Spitman AB; Dezentjé VO; Swen JJ; Moes DJAR; Gelderblom H; Guchelaar HJ
Breast Cancer Res Treat; 2018 Nov; 172(2):401-411. PubMed ID: 30120701
[TBL] [Abstract][Full Text] [Related]
2. Functional genetic variants in the 3'-untranslated region of sulfotransferase isoform 1A1 (SULT1A1) and their effect on enzymatic activity.
Yu X; Dhakal IB; Beggs M; Edavana VK; Williams S; Zhang X; Mercer K; Ning B; Lang NP; Kadlubar FF; Kadlubar S
Toxicol Sci; 2010 Dec; 118(2):391-403. PubMed ID: 20881232
[TBL] [Abstract][Full Text] [Related]
3. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.
Gjerde J; Hauglid M; Breilid H; Lundgren S; Varhaug JE; Kisanga ER; Mellgren G; Steen VM; Lien EA
Ann Oncol; 2008 Jan; 19(1):56-61. PubMed ID: 17947222
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
Sanchez-Spitman A; Dezentjé V; Swen J; Moes DJAR; Böhringer S; Batman E; van Druten E; Smorenburg C; van Bochove A; Zeillemaker A; Jongen L; Los M; Neven P; Gelderblom H; Guchelaar HJ
J Clin Oncol; 2019 Mar; 37(8):636-646. PubMed ID: 30676859
[TBL] [Abstract][Full Text] [Related]
5. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
Wegman P; Elingarami S; Carstensen J; Stål O; Nordenskjöld B; Wingren S
Breast Cancer Res; 2007; 9(1):R7. PubMed ID: 17244352
[TBL] [Abstract][Full Text] [Related]
6. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.
Hennig EE; Piatkowska M; Karczmarski J; Goryca K; Brewczynska E; Jazwiec R; Kluska A; Omiotek R; Paziewska A; Dadlez M; Ostrowski J
BMC Cancer; 2015 Aug; 15():570. PubMed ID: 26232141
[TBL] [Abstract][Full Text] [Related]
7. SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen.
Moyer AM; Suman VJ; Weinshilboum RM; Avula R; Black JL; Safgren SL; Kuffel MJ; Ames MM; Ingle JN; Goetz MP
Pharmacogenomics; 2011 Nov; 12(11):1535-43. PubMed ID: 21961651
[TBL] [Abstract][Full Text] [Related]
8. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.
Wegman P; Vainikka L; Stål O; Nordenskjöld B; Skoog L; Rutqvist LE; Wingren S
Breast Cancer Res; 2005; 7(3):R284-90. PubMed ID: 15987423
[TBL] [Abstract][Full Text] [Related]
9. SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?
Tengström M; Mannermaa A; Kosma VM; Hirvonen A; Kataja V
BMC Cancer; 2012 Jun; 12():257. PubMed ID: 22708928
[TBL] [Abstract][Full Text] [Related]
10. Relationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patients.
Fernández-Santander A; Gaibar M; Novillo A; Romero-Lorca A; Rubio M; Chicharro LM; Tejerina A; Bandrés F
PLoS One; 2013; 8(7):e70183. PubMed ID: 23922954
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
Hertz DL; Deal A; Ibrahim JG; Walko CM; Weck KE; Anderson S; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Graham M; Peppercorn JM; Jones DR; Desta Z; Flockhart DA; Evans JP; McLeod HL; Carey LA; Irvin WJ
Oncologist; 2016 Jul; 21(7):795-803. PubMed ID: 27226358
[TBL] [Abstract][Full Text] [Related]
12. Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy.
Nowell S; Sweeney C; Winters M; Stone A; Lang NP; Hutchins LF; Kadlubar FF; Ambrosone CB
J Natl Cancer Inst; 2002 Nov; 94(21):1635-40. PubMed ID: 12419790
[TBL] [Abstract][Full Text] [Related]
13. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.
Helland T; Henne N; Bifulco E; Naume B; Borgen E; Kristensen VN; Kvaløy JT; Lash TL; Alnæs GIG; van Schaik RH; Janssen EAM; Hustad S; Lien EA; Mellgren G; Søiland H
Breast Cancer Res; 2017 Nov; 19(1):125. PubMed ID: 29183390
[TBL] [Abstract][Full Text] [Related]
14. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.
Antunes MV; Linden R; Santos TV; Wallemacq P; Haufroid V; Classen JF; Andreolla H; Costa N; Fontanive TO; Rosa DD
Ther Drug Monit; 2012 Aug; 34(4):422-31. PubMed ID: 22777153
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer.
Rangel LB; Taraba JL; Frei CR; Smith L; Rodriguez G; Kuhn JG
Breast Cancer Res Treat; 2014 Dec; 148(3):571-80. PubMed ID: 25395315
[TBL] [Abstract][Full Text] [Related]
16. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.
Nowell SA; Ahn J; Rae JM; Scheys JO; Trovato A; Sweeney C; MacLeod SL; Kadlubar FF; Ambrosone CB
Breast Cancer Res Treat; 2005 Jun; 91(3):249-58. PubMed ID: 15952058
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial.
Serrano D; Lazzeroni M; Zambon CF; Macis D; Maisonneuve P; Johansson H; Guerrieri-Gonzaga A; Plebani M; Basso D; Gjerde J; Mellgren G; Rotmensz N; Decensi A; Bonanni B
Pharmacogenomics J; 2011 Apr; 11(2):100-7. PubMed ID: 20309015
[TBL] [Abstract][Full Text] [Related]
18. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
[TBL] [Abstract][Full Text] [Related]
19. The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen.
Sanchez-Spitman AB; Moes DA; Gelderblom H; Dezentjé VO; Swen JJ; Guchelaar HJ
Pharmacogenomics; 2017 Aug; 18(12):1125-1132. PubMed ID: 28745555
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
Dezentjé VO; Opdam FL; Gelderblom H; Hartigh den J; Van der Straaten T; Vree R; Maartense E; Smorenburg CH; Putter H; Dieudonné AS; Neven P; Van de Velde CJ; Nortier JW; Guchelaar HJ
Breast Cancer Res Treat; 2015 Oct; 153(3):583-90. PubMed ID: 26369533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]